Colon cancer: preventive agents and the present status of chemoprevention
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Colorectal cancer (CRC) is one of the most common cancers worldwide and a prevalent cause of morbidity and mortality. CRC has a natural history of transition from a precursor lesion, ie adenomatous polyp to cancer, that spans over 10 to 15 years providing an extended opportunity for intervention and cancer prevention. Suppression of the carcinogenic process by use of pharmacological or natural agents is the cornerstone of chemoprevention. OBJECTIVES: The aim of this review was to give an up-to-date overview on the different agents that had been studied, over the last decade, as chemopreventive agents and the current status of chemoprevention. METHODS: Articles were identified by searches of PubMed and the Internet and reviewed. All articles and other referenced materials were retrieved using the keywords "colon cancer", "adenoma", "chemoprevention", "non steroidal anti-inflammatory drugs", "aspirin", "HMG-CoA reductase inhibitors", "bile acids", "Difluoromethylornithine", "hormone replacement therapy", "mesalamine", "curcumin", and "calcium". Papers were published between 1960 and 2008, with older references selected for historical significance. Only papers published in English were reviewed. RESULTS: Recent preclinical as well as clinical trials have provided data on the potential benefit of a number of drugs and nutritional elements in the field of CRC prevention. Currently, only celecoxib is FDA approved for chemoprevention of CRC and only for high-risk patients with Familial Adenomatous Polyposis (FAP). This is mainly due to cardiovascular toxicity reported in individuals with a personal history of sporadic adenomas. Aspirin and sulindac have also repeatedly demonstrated efficacy in this setting. However, due to increased risk of associated GI toxicity their benefit will have to be weighed against their risk. Combination therapy, using lower doses of each medication, is drawing a great deal of attention and many studies utilizing a variety of chemopreventive agents are presently under study. Promising results have recently been published using sulindac and DFMO. CONCLUSION: Many agents have shown positive results in the field of chemoprevention however, the ideal chemopreventive agent remains to be discovered with great emphasis on need not to harm. Combining different agents may maximize effectiveness while limiting drug toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439 · cited 1×
“In humans, two large trials of simvastatin and pravastatin in patients with coronary artery disease found a reduction in the incidence of colon cancer [48,49] .”
BackgroundCardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Phase III Trial of Ursodeoxycholic Acid To Prevent Colorectal Adenoma Recurrence
Alberts, D. S., Martínez, M. E., Hess, L. M., Einspahr, J. G., Green, S. B., Bhattacharyya, A. K., Guillen, J., Krutzsch, M., Batta, A. K., Salen, G., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji144 · Cited by 247 · cited 1×
“03) in the recurrence of adenomas with high-grade dysplasia [52] .”
Background
Cited by
Terzić, J., Grivennikov, S., Karin, E., & Karin, M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.058 · Cited by 1,974
Chemopreventive effect of dietary polyphenols in colorectal cancer cell lines
Araújo, J. R., Gonçalves, P., & Martel, F. (2011) · Nutrition Research · doi:10.1016/j.nutres.2011.01.006 · Cited by 340
Long, M., Tao, S., Rojo de la Vega, M., Jiang, T., Wen, Q., Park, S. L., Zhang, D. D., & Wondrak, G. T. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0359 · Cited by 86
Chung, K.-S., Choi, H.-E., Shin, J.-S., Cho, E.-J., Cho, Y.-W., Choi, J.-H., Baek, N.-I., & Lee, K.-T. (2015) · Food and Chemical Toxicology · doi:10.1016/j.fct.2014.11.007 · Cited by 14
Metadata
- Authors
- Half, E., & Arber, N.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2009-01-20
- Volume
- 10
- Issue
- 2
- Pages
- 211-219
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2076254399
- Cited by
- 154
- References
- 3
- FWCI
- 14.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Colon cancer: preventive agents and the present status of chemoprevention. https://app.cochat.ai/papers/10.1517/14656560802560153
- The paper
- Half, E., & Arber, N. (2009). Colon cancer: preventive agents and the present status of chemoprevention. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656560802560153
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.